Breast Cancer

Patients and oncologists are prepared to make trade-offs between efficacy and toxicities, but patients appreciate toxicities impacting quality of life while endeavoring to increase survival.
In patients with metastatic hormone receptor–positive breast cancer treated previously with a CDK4/6 inhibitor, there was a lower median progression-free survival benefit from everolimus in combination with exemestane compared with those patients who had not received this combination.
In this study, a high rate of radiation toxicity was observed in patients with advanced breast cancer treated with CDK4/6 inhibitors.
Updated phase 2 study results of lerociclib (G1T38) combined with fulvestrant support continuous dosing without a drug holiday.
In the MONARCH plus study, the majority of abemaciclib-associated diarrhea events were low grade in severity and well managed by antidiarrheal medications, dose omissions, and/or dose reductions.
In a range of groups with PIK3CA alterations, recent findings demonstrate a clear and consistent clinical benefit of alpelisib when combined with fulvestrant, which was detected in circulating tumor DNA by next-generation sequencing.
Updated overall survival results from the phase 3 MONALEESA-7 trial show that in a 4-year extended follow-up study of pre- and perimenopausal patients with hormone receptor–positive, HER2-negative advanced breast cancer, ribociclib plus endocrine therapy exhibited a clinically relevant overall survival benefit.
BYLieve study results show that alpelisib combined with fulvestrant demonstrates clinically meaningful efficacy and manageable toxicity in patients with hormone receptor–positive, HER2-negative, PIK3CA mutation–positive advanced breast cancer.
Analysis from the PALOMA-3 clinical trial showed that the combination of palbociclib and fulvestrant improved overall survival in patients with hormone receptor–positive, HER2-negative advanced breast cancer.
While radiation therapy is not currently used in combination with CDK4/6 inhibitors in clinical trial protocols, findings from this study support future consideration of this approach in clinical studies.
Page 3 of 12
Results 21 - 30 of 118